Sanofi India Q2 FY26: Profit Before Tax Up 19% to ₹112 Crore, Revenue Grows 6%
Sanofi India reported Q2 FY26 results with total net sales up 6% to ₹437.7 crore. Profit before tax grew 19% to ₹112 crore. The insulin portfolio saw 14% growth. Committees were re-constituted effective October 1, 2026.
The financial results show positive growth, and the re-constitution of committees is a routine corporate action. The impact is medium as it reflects continued business performance and organizational adjustments.
The company reported positive financial results with increased profit and sales growth, driven by strong performance in its key portfolios and disciplined cost management.
Sanofi India Limited announced its unaudited financial results for the quarter and half year ended June 30, 2026. The company reported a 6% growth in total net sales compared to the second quarter of 2025, reaching ₹4377 million (₹437.7 crore) for the quarter and ₹9100 million (₹910 crore) for the half year.
Profits before tax and exceptional items increased by 19% to ₹112 crore (₹1123 million) for the quarter, compared to ₹94 crore (₹941 million) in the second quarter of 2025. Profit before tax as a percentage of net sales improved to 27% in Q2 2026 from 24% in Q2 2025. This improvement is attributed to a favorable product mix and disciplined cost management, with operating expenses declining by 5%.
The Insulin portfolio demonstrated strong performance with a 14% growth for the second consecutive quarter, driven by Lantus®, Toujeo®, and Apidra®, along with Soliqua®. The public sector business saw significant acceleration, growing by 70% due to new accounts for Toujeo® and Soliqua®.
Export sales remained stable. The company also announced the re-constitution of its Stakeholders Relationship Committee and Risk Management Committee, effective from October 1, 2026. In light of Mr. Rachid Ayari stepping down as Whole Time Director and Chief Financial Officer on September 30, 2026, his name will be removed from the list of Key Managerial Personnels authorized for disclosures.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.